title: First use of (18)F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy.
abstract: OBJECTIVE
  The authors present the first use of the novel positron emission tomography (PET) apoptosis tracer (18)F-labeled 2-(5-fluoro-pentyl)-2-methyl-malonic acid ((18)F-ML-10) for early-therapy response assessment of a newly diagnosed glioblastoma multiforme (GBM) patient.
  
  
  METHODS
  A 71-year-old male with a newly diagnosed GBM received (18)F-ML-10 PET scans prior to therapy initiation (baseline) and after completing 3 weeks of whole-brain radiation therapy with concomitant temozolomide chemotherapy (early-therapy assessment, ETA). The baseline (18)F-ML-10 PET scan showed increased tracer uptake at the site of the GBM, with highest activity toward the central portion of the tumor. At the ETA time point, a new distribution of tracer uptake was observed compared to baseline. Normalized pixel-by-pixel subtraction of baseline from ETA was used to quantify change in tracer distribution between (18)F-ML-10 PET imaging time points. Results of this analysis showed reduction in (18)F-ML-10 uptake at the site of greatest baseline uptake, but increased uptake around the periphery of the tumor at the early-therapy time point.
  
  
  CONCLUSIONS
  The changing patterns of (18)F-ML-10 uptake between baseline and ETA are suggestive for therapy-induced tumor cellular apoptosis.
authors.affiliation: Department of Bioengineering, University of Pittsburgh Pittsburgh, Pennsylvania.
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Oborski
authors.affiliation: Department of Bioengineering, University of Pittsburgh Pittsburgh, Pennsylvania ; Department of Radiology, University of Pittsburgh Pittsburgh, Pennsylvania.
authors.forename: Charles M
authors.initials: CM
authors.lastname: Laymon
authors.affiliation: Department of Neurology and Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania.
authors.forename: Frank S
authors.initials: FS
authors.lastname: Lieberman
authors.affiliation: Department of Neurology and Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania.
authors.forename: Jan
authors.initials: J
authors.lastname: Drappatz
authors.affiliation: Department of Pathology, Division of Neuropathology, University of Pittsburgh Pittsburgh, Pennsylvania.
authors.forename: Ronald L
authors.initials: RL
authors.lastname: Hamilton
authors.affiliation: Department of Radiology, University of Pittsburgh Pittsburgh, Pennsylvania.
authors.forename: James M
authors.initials: JM
authors.lastname: Mountz
mesh_terms: D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects / Q000528:radiation effects; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000494:pharmacology; D005909:Glioblastoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D008297:Male; D008764:Methylmalonic Acid / Q000031:analogs & derivatives*; D049268:Positron-Emission Tomography / Q000379:methods*; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: C532430:5-fluoropentyl-2-methylmalonic acid; D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D008764:Methylmalonic Acid; D000077204:Temozolomide
keywords: 18F-ML-10; early-therapy response assessment; glioblastoma multiforme; positron emission tomography